FinscoFinsco

AngioDynamics (US.ANGO)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ANGO · YoY: 2026 ANNUAL vs 2025 ANNUAL

MetricValueYoY
FCF Conversion16.4%↓
ROE-21.5%↓
Cash Conversion-→
D/E Ratio0.00↓
Gross Margin54.6%→
US.ANGO (AngioDynamics) | YoY: 2026 ANNUAL vs 2025 ANNUAL


Metric            Value  YoY
----------------------------
FCF Conversion    16.4%    ↓
ROE              -21.5%    ↓
Cash Conversion       -    →
D/E Ratio          0.00    ↓
Gross Margin      54.6%    →
Key Metrics
US.ANGO (AngioDynamics) | YoY: 2026 ANNUAL vs 2025 ANNUAL
Metric Value YoY
----------------------------
FCF Conversion 16.4% ↓
ROE -21.5% ↓
Cash Conversion - →
D/E Ratio 0.00 ↓
Gross Margin 54.6% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies